Table: monthly_update_prescription_drugs_intro_to_the_market_excel , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Hikma Pharmaceuticals USA Inc	00054458249	Mercaptopurine Oral Suspension, 20mg/mL, 100 mL Bottle	2025-02-26	1306.7900	This drug is a generic product; therefore, no marketing and pricing plans are available. This product is sold in the United States only.	None	115294	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Mercaptopurine Oral Suspension is indicated as a therapy for patients with acute lymphocytic leukemia. According to the National Cancer Institute, there are approximately 115,294 people living with acute lymphocytic leukemia in the United States.	None